Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature

Completed · Phase 3

Conditions studied: Growth Disorder

In brief

After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted. All of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height.

Key facts

Study ID
NCT00191074
Run by
Eli Lilly and Company
People needed
11
Starts
2001-02-01
Expected to finish
2006-01-01
Last updated by the study team
2007-03-09

Who can join

Age: 9 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.